Skip to main content

Press Releases

more »
Date Title
Toggle Summary Sienna Biopharmaceuticals Prices Public Offering of Common Stock
WESTLAKE VILLAGE, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $2.50 per share.
Toggle Summary Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock
WESTLAKE VILLAGE, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the
Toggle Summary Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System
-- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solution of silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has potential to expand the $3 billion U.S. laser hair removal market as an effective option for
Toggle Summary Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
WESTLAKE VILLAGE, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna®, is scheduled to present at the 6 th Annual Dermatology Summit, Sunday, Jan.
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to

SEC Filings

more »

Events

more »
Date Title
Summary Toggle Jan 9, 2019 at 2:00 PM EST

J.P. Morgan Healthcare Conference

Location

The Westin St. Francis Hotel, San Francisco
Summary Toggle Dec 12, 2018 at 10:20 AM EST

BMO Capital Markets
Prescriptions for Success Healthcare Conference
Summary Toggle Dec 3, 2018 at 8:15 AM EST

Sienna Biopharmaceuticals SNA-120 Phase 2b Trial Top-line Results Conference Call

Supporting Materials
SNA-120 Phase 2b Trial Top-Line Results 15.5 MB

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Corporate Presentation

Click here to view our Corporate Presentation.

Stock Information

more »
Volume
Today's Open
Previous Close

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

more »
Firm Analyst
J.P. Morgan
 Chris Schott
Cowen
 Ken Cacciatore
BMO Capital Markets
 Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Corporate Governance

Click here to view our Corporate Governance information.

Transfer Agent

more »

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com